- Home
- NRGV vs TLSI Comparison
NRGV vs TLSI Comparison
Compare NRGV & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRGV
- TLSI
- Stock Information
- Founded
- NRGV 2017
- TLSI 2010
- Country
- NRGV United States
- TLSI United States
- Employees
- NRGV N/A
- TLSI N/A
- Industry
- NRGV Industrial Machinery/Components
- TLSI Medical Specialities
- Sector
- NRGV Miscellaneous
- TLSI Health Care
- Exchange
- NRGV Nasdaq
- TLSI Nasdaq
- Market Cap
- NRGV 133.4M
- TLSI 150.0M
- IPO Year
- NRGV N/A
- TLSI N/A
- Fundamental
- Price
- NRGV $1.91
- TLSI $5.01
- Analyst Decision
- NRGV Buy
- TLSI Strong Buy
- Analyst Count
- NRGV 3
- TLSI 5
- Target Price
- NRGV $1.58
- TLSI $10.90
- AVG Volume (30 Days)
- NRGV 1.9M
- TLSI 109.8K
- Earning Date
- NRGV 08-07-2025
- TLSI 08-12-2025
- Dividend Yield
- NRGV N/A
- TLSI N/A
- EPS Growth
- NRGV N/A
- TLSI N/A
- EPS
- NRGV N/A
- TLSI N/A
- Revenue
- NRGV $51,716,000.00
- TLSI $35,990,000.00
- Revenue This Year
- NRGV $314.58
- TLSI $56.79
- Revenue Next Year
- NRGV $39.00
- TLSI $54.15
- P/E Ratio
- NRGV N/A
- TLSI N/A
- Revenue Growth
- NRGV N/A
- TLSI 45.50
- 52 Week Low
- NRGV $0.60
- TLSI $3.42
- 52 Week High
- NRGV $2.70
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- NRGV 62.79
- TLSI 55.11
- Support Level
- NRGV $2.00
- TLSI $4.80
- Resistance Level
- NRGV $2.33
- TLSI $5.24
- Average True Range (ATR)
- NRGV 0.16
- TLSI 0.35
- MACD
- NRGV 0.02
- TLSI 0.02
- Stochastic Oscillator
- NRGV 54.84
- TLSI 72.18
About NRGV Energy Vault Holdings Inc.
Energy Vault Holdings Inc is a grid-scale energy storage company that is driving a faster transition to renewable power by solving the intermittence issues that are inherent to the prevalent sources of renewable energy, solar and wind. Geographical presence in United States, China and Other. Majority of its revenue comes from U.S.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.